Evidence map›Paper›PMID 40487459›Full record

ArticlePublic health action2025

Isoniazid-resistant TB and associated factors in Ethiopia.

S Moga, T Abebe, K Bobosha, A Alemu, G Diriba, K R V Harrington, R H Lyles, H M Blumberg, R R Kempker

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Public health action, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Genomic characterization of drug-resistantFrontiers in tuberculosis · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

S MogaAddis Ababa University (AAU), Department of Microbiology, Immunology, and Parasitology, School of Medicine, College of Health Sciences, Addis Ababa, Ethiopia.
T AbebeAddis Ababa University (AAU), Department of Microbiology, Immunology, and Parasitology, School of Medicine, College of Health Sciences, Addis Ababa, Ethiopia.
K BoboshaArmauer Hansen Research Institute (AHRI), Mycobacterial Diseases Research Directorate, Addis Ababa, Ethiopia.
A AlemuEthiopian Public Health Institute (EPHI), Infectious Diseases Research Directorate, Addis Ababa, Ethiopia.
G DiribaEthiopian Public Health Institute (EPHI), Infectious Diseases Research Directorate, Addis Ababa, Ethiopia.
K R V HarringtonEmory University Rollins School of Public Health, Department of Epidemiology, Atlanta, GA, USA.
R H LylesEmory University Rollins School of Public Health, Department of Biostatistics and Bioinformatics, Atlanta, GA, USA.
H M BlumbergEmory University Rollins School of Public Health, Departments of Epidemiology and Global Health, Atlanta, GA, USA.
R R KempkerEmory University School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, GA, USA.

Funding

Emory/Georgia TB Research Advancement Center (TRAC)P30AI168386 · NIAID · EMORY UNIVERSITY · PI Neel Rajnikant Gandhi · 2022 to 2026
$5.8M
Ethiopia-Emory TB Research Training ProgramD43TW009127 · FIC · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Kidist Bobosha · 2013 to 2026
$3.4M
FIC NIH HHS D43 TW009127NIAID NIH HHS P30 AI168386
6 · The paper itself

Abstract

backgroundIsoniazid-resistant, rifampicin-susceptible

methodsA cross-sectional study was conducted to determine the magnitude of Hr-TB, and to compare characteristics of persons with Hr-TB to those with multidrug-resistant TB (MDR-TB) and INH/RMP-susceptible TB identified during the National Drug Resistance Survey from 2017-2019.

resultsAmong 1927

conclusionsHr-TB is the most prevalent type of DR-TB in Ethiopia and varies among regional states. Given the lack of identifiable clinical factors associated with Hr-TB, we recommend screening all bacteriologically confirmed TB cases for INH resistance at baseline.

Indexed as

drug-resistant TBDSTMDR-TBM. tuberculosistuberculosis

Identifiers

PMID40487459
PMCPMC12143246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.